Dyne Therapeutics to Host Virtual Research and Development Day on Wednesday, October 13, 2021
Dyne Therapeutics (Nasdaq: DYN) is hosting a virtual Research and Development Day on October 13, 2021, from 8:00 – 10:30 a.m. ET. The event, titled “The Muscle to Move to the Clinic”, will showcase preclinical data for the company’s programs targeting myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD). Leading experts, including Dr. Valeria Sansone and Dr. John Day, will present updates and discuss advancing these programs into clinical trials. A live webcast will be available with a replay for 90 days.
- None.
- None.
- “The Muscle to Move to the Clinic” Event Will Highlight Preclinical Data Supporting Advancement of Dyne’s DM1 and DMD Programs Toward Clinical Trials and Anticipated Timelines, and Feature Leading Experts in Both Disease Areas -
WALTHAM, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, will host a virtual Research and Development Day on Wednesday, October 13, 2021 from 8:00 – 10:30 a.m. ET. “The Muscle to Move to the Clinic” event will focus on Dyne’s co-lead development programs for rare muscle diseases, myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD).
The program will feature presentations, discussion and Q&A with the following speakers:
- Valeria Sansone, M.D., Ph.D., Clinical and Scientific Director, Clinical Center NeMO, Milan; Associate Professor of Neurology, University of Milan
- John Day, M.D., Ph.D., Professor of Neurology and Pediatrics, and Director of the Neuromuscular Division, Stanford Neuroscience Health Center
- Joshua Brumm, President and Chief Executive Officer: Dyne’s mission, key program updates and milestones
- Oxana Beskrovnaya, Ph.D., Chief Scientific Officer: FORCE™ platform and review of preclinical data for Dyne’s DM1 and DMD programs, including new in vivo data presented during the World Muscle Society 2021 Virtual Congress and the 2021 Muscle Study Group Annual Scientific Meeting
- Wildon Farwell, M.D., MPH, Chief Medical Officer: preparations for advancing both programs into the clinic and initial plans for clinical trials
A live webcast of the event will be available in the Events & Presentations page of the Investors & Media section of Dyne’s website and a replay will be accessible for 90 days following the presentation. An accompanying slide presentation will also be available. To register for the live webcast and replay, please visit: https://investors.dyne-tx.com/events/event-details/dyne-rd-day.
About Dyne Therapeutics
Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approaches. Dyne’s broad portfolio of therapeutic candidates for serious muscle diseases includes programs for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on Twitter, LinkedIn and Facebook.
Contact:
Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203
FAQ
What is the date of Dyne Therapeutics' R&D Day?
What will be discussed during the R&D Day for DYN?
Who are the key speakers at Dyne's R&D Day?
Will there be a live webcast of the event for DYN?
What are the main topics covered during the R&D Day for Dyne Therapeutics?
